Rifaximin
- Generic Name
- Rifaximin
- Brand Names
- Xifaxan, Zaxine
- Drug Type
- Small Molecule
- Chemical Formula
- C43H51N3O11
- CAS Number
- 80621-81-4
- Unique Ingredient Identifier
- L36O5T016N
- Background
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalop...
- Indication
Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in ...
- Associated Conditions
- Bacterial Infections, Clostridium difficile infection recurrence, Hepatic Encephalopathy (HE), Irritable Bowel Syndrome (IBS), Traveler's Diarrhea
- Associated Therapies
- -
Rifaximin for Chronic Immune Activation in People With HIV
- First Posted Date
- 2013-06-03
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 46
- Registration Number
- NCT01866826
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Walter Reed National Medical Center, Bethesda, Maryland, United States
🇺🇸National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT01846663
- Locations
- 🇺🇸
Loma Linda University Medical Center Transplantation Institute, Loma Linda, California, United States
🇺🇸University of Southern Califorina Keck School Of Medicine, Los Angeles, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Quality of Life and Nutritional Improvements in Cirrhotic Patients
- Conditions
- Interventions
- First Posted Date
- 2013-04-29
- Last Posted Date
- 2013-09-23
- Lead Sponsor
- Tampa General Hospital
- Target Recruit Count
- 4
- Registration Number
- NCT01842113
- Locations
- 🇺🇸
Tampa General Medical Group, Tampa, Florida, United States
The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy
- Conditions
- Interventions
- First Posted Date
- 2013-04-29
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 222
- Registration Number
- NCT01842581
- Locations
- 🇺🇸
The Center for Liver and Biliary Disease, Baltimore, Maryland, United States
🇺🇸Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸Asheville Gastroenterology Associates, PA, Asheville, North Carolina, United States
Evaluation of the Metabolome in Diverticular Disease
- First Posted Date
- 2013-04-15
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- S.Eugenio Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT01831323
- Locations
- 🇮🇹
Sant'Eugenio Hospital, Rome, RM, Italy
Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis
- First Posted Date
- 2013-01-16
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Copenhagen University Hospital, Hvidovre
- Target Recruit Count
- 54
- Registration Number
- NCT01769040
- Locations
- 🇩🇰
Copenhagen University hospital Hvidovre, Hvidovre, Denmark
A Pilot Study of Xifaxan to Treat Patients With PSC
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 16
- Registration Number
- NCT01695174
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea
- First Posted Date
- 2012-08-21
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- University of Nottingham
- Target Recruit Count
- 151
- Registration Number
- NCT01670149
- Locations
- 🇬🇧
Nottingham Clinical Trials Unit (NCTU), Queen's Medical Centre, Nottingham, Nottinghamshire, United Kingdom
Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth
- First Posted Date
- 2012-08-10
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 49
- Registration Number
- NCT01662791
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Douglas T. Dieterich
- Registration Number
- NCT01654939
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.